RT Journal Article
SR Electronic
T1 Is ATP7B a Predictive Marker in Patients With Ovarian Carcinoma Treated With Platinum-Taxane Combination Chemotherapy?
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 60
OP 64
DO 10.1097/IGC.0b013e318275afef
VO 23
IS 1
A1 Hiroshi Katagiri
A1 Kentaro Nakayama
A1 Mohammed Tanjimur Rahman
A1 Munmun Rahman
A1 Atsuko Katagiri
A1 Tomoka Ishibashi
A1 Masako Ishikawa
A1 Kouji Iida
A1 Satoru Nakayama
A1 Yoshiro Otsuki
A1 Kohji Miyazaki
YR 2013
UL http://ijgc.bmj.com/content/23/1/60.abstract
AB Objective This study examined the prognostic significance of copper-transporting P-type adenosine triphosphatase (ATP7B) expression in patients with ovarian carcinoma treated with platinum-taxane combination chemotherapy.Methods Expression of ATP7B in ovarian carcinoma was assessed by immunohistochemistry and clinical data collected by retrospective review of medical charts.Results Overexpression of ATP7B was identified in 25 (29.1%) of 86 ovarian carcinomas. The frequency of ATP7B expression in clear cell carcinomas was significantly higher than that in serous high-grade carcinomas (P < 0.05). We observed no statistically significant correlations between high ATP7B protein expression and either disease-free survival (P = 0.722) or overall survival (P = 0.389).Conclusions Our study is the first to demonstrate a lack of statistically significant differences between ATP7B positive and negative cases with respect to prognosis of patients with ovarian carcinoma treated with a platinum-taxane combination regimen. However, that ATP7B expression in clear cell carcinomas was significantly higher than that in serous carcinomas may partially explain the difference in chemotherapeutic response and prognosis between patients with these 2 types of carcinomas.